期刊文献+

希罗达治疗中晚期大肠癌的临床研究

下载PDF
导出
摘要 目的观察使用希罗达治疗晚期大肠癌的临床疗效。方法希罗达每日2510mg/m2,每日总量分早晚2次餐后口服,连续2周,间隔1周,每3周重复。每例患者至少2个周期的治疗。结果42例患者中,完全缓解1例,部分缓解14例,稳定23例,进展4例。总有效率为35.7%。不良反应为轻度恶心、腹泻、口角炎、疲劳及手足综合征等。结论希罗达是治疗中晚期大肠癌的有效药物,其不良反应轻微,使用方便,可延长患者的生存期,提高患者的生活质量。
出处 《四川医学》 CAS 2007年第1期95-96,共2页 Sichuan Medical Journal
  • 相关文献

参考文献4

  • 1shikawa T,Utoh M,Sawada N,et al.Capecitabine,a new oral fluoropyrimidine carbamate selectively delivers fluorouracil to tumor tissues in human cancer xenografts[J].Biochem Pharmacol,1998,55:1091~1097
  • 2Miwa M,Ura M,Nishida M,et al.Design of a novel oral fluoropyrimidine carbamate,capecitabine,which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue[J].Eur J Cancer,1998,34:1274~1281
  • 3Cox JV,Pazdur R,Thibault A,et al.A phase Ⅲ trial of Xeloda(capecitabine)in previously untreated advanced/metastatic colorectal cancer[J].Proc Am Soc Clin Oncol,1999,18:1016~1018
  • 4王宝成,毕经旺,李志.靶向化疗——氟化嘧啶类药物的研究进展[J].国外医学(肿瘤学分册),2001,28(6):447-451. 被引量:73

二级参考文献16

  • 1Koizumi W, Saigenji K, Nakamaru N,et al. Prediction of response to 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor [J]. Oncology,1999;56(3) :215-222.
  • 2Takiguchi N, Nakajima N, Saitoh N, et al. A phase Ⅲ randomized study comparing oral doxifluridine and oral 5-fluorouracil after curative resection of gastric cancer[J]. Int J Oncol, 2000 , 6 (5): 1021-1027.
  • 3Miyadera K, Sumizawa T, Haraguchi M, et al . Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase[J]. Cancer Res,1995,55(8): 1687-1690.
  • 4Maeda K, Chung YS, Ogawa Y, et al. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma[J]. Br J Cancer, 1996,73 (8): 884-888.
  • 5Mata JF, Garcia Manteiga JM, Lostao MP, et al. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5 [Prime] - deoxy- 5- fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug[J ]. Mol Pharmacol,2001,59(6): 1542.
  • 6Miwa M, UraM, NishidaM, etal. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue[J]. Eur J Cancer, 1998,34(8) :1274-1281.
  • 7Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine[J]. Clin Pharmacokinet,2001,40(2) :85-104.
  • 8Blum JL, Jones SE, Buxdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer[J]. J Clin Oncol, 1999,17 ( 2): 485 -493.
  • 9O'shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase Ⅱ study of Xeloda (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged≥55 years[J]. Proc Am Soc Clin Oncol, 1998,17:398-406.
  • 10O'Reilly SM,Moiseyenko V,Talbot DC, et al. A randomized phase Ⅱ study of Xeloda (capecitabine)vs paclitaxel in breast cancer patients failing previous anthracycline therapy[J]. Proc Am Soc Clin Oncol, 1998,17: 627-635.

共引文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部